The supplement industry is facing a reckoning over the quality of evidence supporting its products. A recent attempt to design a rigorous clinical trial for a botanical extract revealed systemic barriers to research, highlighting a fundamental tension between consumer demand for proof and a business model that often discourages it.
Approximately 75% of U.S. Adults seize at least one supplement, often seeking solutions for health concerns not adequately addressed by conventional medicine, according to a 2023 survey. However, many “nutraceuticals” – dietary supplements used for medicinal purposes – lack robust scientific backing. Peer-reviewed trials are scarce, and those that exist are frequently limited by small sample sizes, methodological flaws, or an inability to demonstrate conclusive results. The National Institutes of Health cautions against assuming supplements can reverse disease progression.
The core issue, as illustrated by clinical research scientist Elise Felicione’s recent experience, is the economic disincentive for rigorous testing. A supplement company approached Felicione seeking a publication-quality, randomized controlled trial (RCT) for a botanical extract. The company insisted on a limited budget, a small participant pool, and an extensive list of secondary endpoints. Felicione found that achieving a scientifically sound study within those constraints would require significant compromises to the study design and a drastic reduction in her investigator fee.
This experience underscored a broader problem: the nutraceutical sector operates under structural constraints that hinder robust research. Felicione identified five key tensions. The first is the conflict between public demand for evidence and a system that doesn’t prioritize it. Unlike pharmaceuticals, which benefit from patent exclusivity to recoup the costs of clinical trials, botanical supplements are often difficult to patent, meaning any company proving a benefit for an ingredient allows competitors to freely capitalize on that research.
The escalating cost of clinical trials further exacerbates the problem. Increasingly complex designs and evidentiary standards have made comprehensive research financially prohibitive for many nutraceutical firms. Large pharmaceutical companies can afford full clinical development, while most supplement manufacturers are effectively priced out of conducting rigorous trials.
A second tension lies in balancing realistic costs with study quality. Many companies underestimate the resources required for credible trials, assuming a small-scale study with basic surveys will suffice. However, reliable trials demand validated outcomes, safety monitoring, trained personnel, statistical expertise, and ethical review. Even small RCTs can easily exceed $150,000. When budgets are tight, sample sizes and follow-up durations are often reduced, diminishing the study’s ability to detect meaningful effects.
The rise of decentralized trials – studies conducted remotely using apps and wearable devices – is often presented as a cost-saving measure. However, Felicione cautions that costs don’t disappear; they simply shift. Without on-site supervision, ensuring data consistency and participant adherence requires increased effort from a central research team, potentially negating the anticipated savings.
A third tension arises from regulatory limitations. Companies cannot legally claim their supplements prevent, treat, or cure disease. This constraint forces researchers to frame studies around softer endpoints, such as “maintaining daily energy levels,” rather than targeting clinical improvements or disease pathways. This shift compromises the scientific rigor and limits the potential for conclusive findings.
Felicione similarly points out that a single RCT is insufficient to establish a product’s efficacy. A comprehensive understanding requires preliminary studies examining pharmacokinetics (how the body processes the substance) and pharmacodynamics (what the substance does to the body), optimal dosage, potential interactions, and safety profiles. Skipping these foundational steps increases the risk of a failed pivotal RCT.
Finally, there’s a mismatch between research timelines and commercial pressures. Supplement companies often operate on quarterly cycles, seeking rapid results to support marketing claims. This urgency can lead to shortcuts, such as shortened follow-up periods and a focus on “publishable” results rather than conclusive evidence.
Felicione proposes several solutions to address these challenges, including shared-cost trials across multiple brands, platform designs for evaluating ingredients once for the benefit of all, consortia to develop validated biomarkers, academic-industry partnerships focused on research questions rather than marketing, transparent cost expectations, and open registration and publication of trial results. Costco, for example, offers a range of multivitamins and supplements, including Kirkland Signature Adult Multivitamin Gummies, which provide an excellent source of 10 essential vitamins, but the extent of independent research backing these products remains largely undisclosed.
“Supplements are here to stay,” Felicione concludes. “If we want to stop arguing about whether [a supplement] works, or if it is safe, and start knowing, we need a research ecosystem capable of answering the question realistically, rigorously, and sustainably.”
